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Inositol 1,4,5-trisphosphate (IP3) is a ubiquitous intracellular messenger regulating diverse functions in almost all mammalian cell types. It is
generated by membrane receptors that couple to phospholipase C (PLC), an enzyme which liberates IP3 from phosphatidylinositol 4,5-
bisphosphate (PIP2). The major action of IP3, which is hydrophilic and thus translocates from the membrane into the cytoplasm, is to induce Ca
2+
release from endogenous stores through IP3 receptors (IP3Rs). Cardiac excitation–contraction coupling relies largely on ryanodine receptor (RyR)-
induced Ca2+ release from the sarcoplasmic reticulum. Myocytes express a significantly larger number of RyRs compared to IP3Rs (~100:1), and
furthermore they experience substantial fluxes of Ca2+ with each heartbeat. Therefore, the role of IP3 and IP3-mediated Ca
2+ signaling in cardiac
myocytes has long been enigmatic. Recent evidence, however, indicates that despite their paucity cardiac IP3Rs may play crucial roles in
regulating diverse cardiac functions. Strategic localization of IP3Rs in cytoplasmic compartments and the nucleus enables them to participate in
subsarcolemmal, bulk cytoplasmic and nuclear Ca2+ signaling in embryonic stem cell-derived and neonatal cardiomyocytes, and in adult cardiac
myocytes from the atria and ventricles. Intriguingly, expression of both IP3Rs and membrane receptors that couple to PLC/IP3 signaling is altered
in cardiac disease such as atrial fibrillation or heart failure, suggesting the involvement of IP3 signaling in the pathology of these diseases. Thus,
IP3 exerts important physiological and pathological functions in the heart, ranging from the regulation of pacemaking, excitation–contraction and
excitation–transcription coupling to the initiation and/or progression of arrhythmias, hypertrophy and heart failure.
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A quarter of a century ago it was shown that D-myo inositol
1,4,5-trisphosphate (IP3) releases Ca
2+ from a non-mitochondrial
internal Ca2+ store [1]. Since this hallmark discovery, IP3 has
emerged as a ubiquitous intracellular messenger, releasing Ca2+
from stores through activation of IP3 receptors (IP3Rs) in almost
all eukaryotic cells. The major IP3-sensitive intracellular Ca
2+
store is the endoplasmic reticulum. However, IP3 has also been
shown to release Ca2+ stored in other compartments, such as the
Golgi and the nuclear envelope [2]. In addition, IP3Rs are
present on the plasma membrane of some cell types, where they
can gate Ca2+ influx [3]. A crucial role for IP3-dependent Ca
2+
release has been demonstrated in many mammalian cell types,
ranging from tiny platelets, where it initiates blood clotting, to
the impressive dendritic trees of cerebellar Purkinje neurons,
where it is involved in the regulation of motor function. In the
cardiovascular system, IP3-induced Ca
2+ release from the
sarcoplasmic reticulum (SR) plays a key role in pharmaco-
mechanical coupling in smooth muscle cells of the vasculature,
and thus in the regulation of peripheral resistance and blood
pressure. Despite being recognized as a potential messenger in
cardiac myocytes nearly two decades ago, the role of IP3 has
been enigmatic. However, a number of recent reports have
begun to unravel the physiological and potentially pathological
actions of IP3 within the heart.
2. The ABC of IP3: where does it come from and where
does it go?
IP3 is generated by hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) through phosphoinositide-specific phos-
pholipase C (PLC). PIP2 is a relatively minor phospholipid
(∼1% of total anionic phospholipids), but it is the main
polyphosphoinositide in the sarcolemma. Its concentration in
myocardium is in the range of 10–30 μM or 150–450 pmol/mg
protein [4,5]. PIP2 itself serves important signaling functions,
including the regulation of ion channels and transporters and the
anchoring of cytoskeletal proteins at the membrane [6,7].
Furthermore, it is the precursor of phosphatidylinositol 3,4,5-
trisphosphate (PIP3), a phosphoinositide involved in cell
signaling. There are at least 13 phosphoinositide-specific PLC
isoforms grouped into six subfamilies: β, γ, δ, ɛ, η and ζ [8,9].
Members of the β, γ, δ and ɛ subfamilies are expressed incardiac myocytes. PLCs may be activated by heptahelical G
protein-coupled receptors (PLCβ), receptor tyrosine kinases
(PLCγ), PIP2 and Ca
2+ (PLCδ) or Ras (PLCɛ). Consequently,
many transmitters, neurohormonal factors, hormones and other
stimuli (e.g. stretch) may increase IP3 concentration and activate
IP3-induced Ca
2+ release in cardiac myocytes downstream of
PLC activation. Upon stimulation, intracellular IP3, or inositol
phosphate concentration in general, has been shown to increase
by a factor of N12 [10]. However, it should be pointed out that
most of these data were determined from assays of measuring
total inositol phosphate accumulation over time (in the presence
of the inositol monophosphatase inhibitor Li+). Such measure-
ments do not reflect the in vivo steady-state IP3 increase, which
is likely to be quite modest. Recently, the concentration of free
IP3 was estimated directly using a novel FRET-based biosensor.
Following maximal stimulation of α-adrenergic and endothelin
receptors, free IP3 in cardiac myocytes increased to ~30 nM
[11]. While such biosensors are useful for detecting genuine
increases in IP3 concentration, they are less helpful in revealing
the kinetics of IP3 turnover, since binding of IP3 to the probe
buffers the molecule and protects it from hydrolyzing enzymes.
Based on modeling studies, it was estimated that stimulation of
atrial myocytes with endothelin transiently increases IP3
concentration from a basal value of ~15 nM to a maximal
value of ~35 nM within ~400 s, after which the IP3 level
gradually declines and returns to baseline within tens of minutes
[12]. A note of caution as to the quantitative results obtained
with isolated myocytes is warranted though, since careful
studies indicate that PIP2 and inositol phosphate levels drop
dramatically during the isolation procedure [13,14].
Because IP3 is hydrophilic, it translocates from the
sarcolemma to the cytoplasm upon formation from PIP2. The
main cytoplasmic target of IP3 is IP3Rs in the membrane of the
ER/SR. There are three IP3R isoforms, denoted type 1, type 2
and type 3. Current evidence suggests that the heart expresses all
three IP3R isoforms, although there is some inconsistency in the
literature regarding their relative ratios in different cardiac cells.
It has been proposed that type 1 IP3Rs are dominant in human
atrial and rat Purkinje myocytes [15,16], whereas atrial and
ventricular myocytes from most other animal species express
predominantly type 2 IP3R and, to a lesser extent, type 3 IP3R
(e.g. [17,18]). Overall, the majority of studies have concluded
that the most prevalent IP3R isoform within contractile cardio-
myocytes is type 2 (see Table 1). The few reports describing
Table 1
Expression of IP3R isoforms in adult myocardium
Species IP3R isoform Specimen Methods Confirmed in myocytes? Findings Reference
Bovine 1 A, V, CS WB, IHC, IP3 binding Yes IP3R1: PNAVNNA, V [16]
Canine 1, 2 LA tissue, myocytes RT-PCR, WB, IHC Yes IP3R1 in cyto; IP3R2 in cyto, NE,
ID; IP3R1,2 up in AF
[170]
Ferret, Rat 1, 2, 3 Heart, V myocytes RNA analyses, IP3
binding, IP3R
reconstitution
Yes (IP3R2,3) IP3R1 predominant in myocardium,




Human 1 LV, RV, Septum NB, in situ
hybridization
Yes IP3R1 up in HF [19]
Human 1 RA tissue RT-PCR, WB, IHC Yes IP3R1 in cyto, NE; IP3R1 up in AF [15]
Human 1 RA tissue RT-PCR No IP3R1 up in AF [169]
Human 1, 2, 3 RA tissue RT-PCR No IP3R1,2,3 down in diabetes [184]
Mouse n.d. Heart; V myocytes WB, ICC Yes Striated pattern in cyto [142]
Mouse n.d. Heart; V myocytes WB, ICC Yes Striated pattern in cyto; colocalization
with NCX
[179]
Mouse 1, 2 Heart WB No No changes in diabetes [183]
Mouse 1, 2, 3 A, V WB No IP3R2≫ IP3R1,3; IP3R2: ANV [17]
Rabbit 2 LV myocytes WB Yes IP3R2 up in HF [202]
Rabbit 2, 3 A, V myocytes WB Yes IP3R2,3: ANV [41]
Rat n.d. Heart, A, V WB, IHC, EM Yes IP3R in ID in A, V [203]
Rat n.d. Heart, A, V RNA analyses, WB,
IHC, in situ
hybridization
Yes IP3R expression in cardiomyocytes
(RyR:IP3R≈50:1)
[54]
Rat n.d. Heart, A, V, CS RNA analyses, in situ
hybridization
Yes IP3R: CSNA=V; Senescence: ANV [204]
Rat 1, 2, 3 A, V, Purkinje RT-PCR, WB, ICC,
IP3 binding
Yes (IP3R2) ANV; IP3R2 in A myocytes in
subsarcolemmal SR
[58]
Rat 2 A myocytes ICC Yes IP3R2 colocalizes with RyR in
subsarcolemmal SR
[63]
Rat 1, 2 A, V RT-PCR WB No IP3R1,2: LANRA≫LV=RV;
IP3R1,2 up by stress in
glucocorticoid-dependent manner
[138]
Rat 2 Heart (nuclear fraction),
V myocytes
WB, ICC Yes IP3R2 predominant in NE [18]
Rat 1 LA, LV RT-PCR, WB No IP3R1 down after depletion of
catecholamines
[205]
Rat 2 Heart RT-PCR, WB No IP3R2 down in diabetes [185]
Rat 1, 2, 3 LA, LV, RA, RV RT-PCR, WB No IP3R1,2 up with aging [168]
Abbreviations: A, atrium; AF, atrial fibrillation; AV, atrio-ventricular; CS, conduction system; cyto, cytoplasm; EM, electron microscopy; HF, heart failure; ICC,
immunocytochemistry; ID, intercalated discs; IHC, immunohistochemistry; L, left; NCX, Na+/Ca2+ exchanger; NB, Northern blotting; n.d., not determined; NE,
nuclear envelope; P, Purkinje; R, right; RT-PCR, reverse transcription or real time polymerase chain reaction; V, ventricle; WB, Western blotting.
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differences in IP3R expression between species, or that the
probes employed lacked specificity.
The IP3R isoforms vary with respect to IP3 affinity, activation
and inactivation by Ca2+, regulation by ATP, phosphorylation
and other modulatory factors (e.g. [20,21]). It is believed that
subtle variations in the sensitivity of the three IP3R isoforms to
such allosteric regulators can modulate the biophysical proper-
ties of the channels. Thus, depending on the expression and
subcellular distribution of particular IP3R isoforms, cells may
respond to alterations in IP3, Ca
2+ and other modulators quite
differently. Furthermore, IP3Rs form macromolecular signaling
complexes with other proteins including ankyrin B, chromo-
granin A and B, cytochrome c, ERp44, Homer, IP3R-binding
protein released with IP3 (IRBIT), the Na
+/K+ pump, protein
phosphatases 1 and 2A, receptor for activated C kinase 1
(RACK1) and others (for reviews, see [22–24]). The interaction
of specific accessory proteins has been demonstrated to eitherpositively or negatively regulate IP3R opening, with consequent
alteration of cellular Ca2+ signals (e.g. [25,26]). Although most
of the data exploring IP3R-binding proteins has been derived
from studies of neuronal IP3Rs, it is likely that cardiac IP3Rs
form similar macromolecular complexes. As yet, only Ca2+- and
calmodulin-dependent protein kinase II (CaMKII) has been
identified as an accessory protein of cardiac IP3Rs [18].
An intriguing aspect of IP3 signaling is the presence of the
entire phosphoinositide signaling network in the nucleus [27]. In
addition, many receptors that act as signal transducers at the cell
membrane are also found in the nuclear envelope (e.g. ETA and
ETB receptors [28]) where they might activate a nuclear PIP2-
PLC-IP3 cascade. The mechanism for stimulation of nuclear
hormone receptors is not entirely clear, although it has been
suggested that activated receptors can be internalized from the
surface of cells and translocated to the nucleus where they
engage signaling pathways. It is therefore plausible that nuclei
may locally generate their own IP3. Alternatively, given that IP3
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plasma membrane may be sufficient for activation of IP3Rs
throughout a cell. The particular interest in cardiac nuclear IP3
signaling derives from a number of recent studies that have
demonstrated expression of IP3Rs within or around the nucleus
in cardiac myocytes [18], and involvement of perinuclear Ca2+
signals in the regulation of kinases (e.g. nuclear CaMKII),
transcription and nuclear pores. This concept is discussed in
more detail below.
It is important to realize that the PIP2-PLC-IP3 cascade is just
a small part of a much larger signaling network, the inositide
metabolome, which encompasses more than 80 gene products
involved in the regulation of phosphatidylinositol phosphates
and inositol phosphates. The inositide metabolome includes
lipid kinases and phosphatases, lipases, inositol phosphate
kinases and phosphatases (reviewed in [30]). Inositol polypho-
sphates derived from IP3 may be signaling molecules in their
own right. In particular, IP4, IP5 and IP6 have been implicated in
the regulation of nuclear functions (gene expression, chromatin
remodeling, mRNA export and RNA editing). This adds to the
complexity of IP3 signaling and suggests that the potential roles
of IP3 go beyond the release of Ca
2+ from internal stores. Higher
inositol polyphosphates, including IP4, IP5 and IP6, have been
detected in the heart [31], as well as high affinity binding sites
for IP4 and IP6 [32,33]. However, their physiological functions
in cardiac myocytes remain poorly understood.
3. Tools to study cardiac IP3 signaling
Numerous tools are available to study cellular IP3 signaling.
They can be grouped into (A) methods to measure intracellular
IP3 levels, (B) pharmacological tools to manipulate IP3 levels,
IP3 production and degradation, and the IP3 receptor, and most
recently (C) approaches that involve genetic manipulation of the
intracellular IP3 signaling cascade and the generation of
transgenic animals with an altered IP3 secondmessenger system.
(A) Of great interest for many years has been the quantitative
determination of intracellular IP3 levels. Until very recently, the
real-time study of IP3 formation, concentration dynamics and
spatial distribution at the level of single living cells has not been
possible. Instead, measurements have relied upon destructive
methodologies [34–37]. These assays essentially rely on whole
cell extracts for mass analysis by competition binding, gas
chromatography/mass spectrometry and ion exchange chroma-
tography, or metabolic measurements of radio-labeled IP3
precursors and degradation products. While these methods
have generated important insights into cellular IP3 dynamics,
they are rather limited in deciphering the spatiotemporal
organization of the IP3 second messenger system at the cellular
and subcellular level. Recent developments, however, have seen
the arrival of novel fluorescent probes to study intracellular IP3
dynamics. For example, a biosensor derived from the IP3
binding domain of type-3 IP3R, termed ‘LIBRA’, was employed
to measure IP3 concentrations in living cells [38]. Similarly, the
intracellular translocation of a pleckstrin homology domain from
phospholipase C∂1 fused to GFP was used to estimate [IP3] [39],
and to measure agonist-induced oscillatory changes of IP3concentration [40]. A recent study reported the construction and
characterization of prototypic fluorescent biosensors that allow
quantitative measurements of cellular IP3 levels in a living cell
with temporal and spatial resolution [11]. These sensors (termed
FIRE-1 and -3, for ‘Fluorescent IP3 Responsive Element’ type-1
and -3) utilized the IP3R type-1 and type-3 ligand-binding
domains expressed as chimeras terminally linked to CFP and
YFP, and which could be used as FRET indicators of IP3. These
constructs have been successfully employed to measure [IP3] in
neonatal and adult ventricular myocytes with high temporal and
subcellular spatial resolution. For example, in FIRE-1-expres-
sing ventricular myocytes, the agonists endothelin-1, pheny-
lephrine and angiotensin II all produced rapid and spatially
resolved increases of IP3 concentration, with free IP3 levels
rising to 30 nM. A point source of IP3, experimentally achieved
by membrane rupture with a patch pipette containing IP3,
allowed detailed spatiotemporal monitoring of intracellular IP3
diffusion, revealing that IP3 diffusion into the nucleus occurred
with a delay, and that the elevation of nuclear IP3 concentration
had a blunted rise compared to that in the cytoplasm.
Furthermore, stimulation with endothelin-1 (100 nM) caused
[IP3] to rise more rapidly and to higher levels in the cytoplasm as
compared with the nucleus. Average data indicate that the
amplitude of rise in nuclear [IP3] was 70±9% of that in the
cytoplasm, and the t1⁄2 was about twice as long (1.3 min vs. 0.7
min) [11]. Clearly, these new biosensors are exciting and
promising novel tools to study IP3 dynamics at high temporal
and spatial resolution in intact living cells, although their
potential to buffer IP3 has to be taken into account.
(B) More conventional, but nonetheless invaluable tools for
the study of IP3 signaling are pharmacological agents that
interfere with the IP3 signaling cascade. Some commonly used
reagents are blockers of IP3 formation (e.g. the PLC inhibitor
U73122 and its negative control U73343), or antagonists of the
IP3 receptor (e.g. heparin, 2 aminoethoxydiphenyl borate (2-
APB), xestospongins, curcumin). Like many pharmacological
inhibitors, these tools all suffer from variable degrees of
specificity, have numerous intracellular targets and unwanted
side effects or lack membrane permeability (for discussion see
[41–43]). Recently developed membrane-permeable forms of
IP3R agonists [44] and IP3 species that can be activated
photolytically [45,46] have further expanded the repertoire of
tools for studying IP3 signaling.
(C) Molecular technologies are also beginning to be
employed to explore cardiac IP3 function. In particular, the
generation of animals or cells with genetically altered IP3
signaling pathways, and the development of transgenic animals.
Due to the inherent nature of the rapid developments in this field,
we will limit our review to two exemplary reports. The
adenoviral-mediated expression of an IP3 affinity trap (which
consisted of the ligand-binding domain of the rat type-1 IP3R;
also known as an ‘IP3 sponge’) has been successfully used to
abolish IP3-evoked effects on Ca
2+ signaling in rabbit
ventricular myocytes [41]. The IP3 sponge represents an
experimental tool that can complement or replace pharmacolo-
gical IP3R blockers, and specifically attenuate IP3 signaling.
Potentially even better than the IP3 sponge would be the
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phosphatase), which does not necessarily have to be present at
1:1 stoichiometry to completely clamp IP3 signaling. With
respect to transgenic animals, it has been shown that the positive
inotropic and pro-arrhythmic effects of endothelin-1 were
completely abolished in mouse atrial cells lacking the IP3R
type-2 isoform [17]. This loss of response to endothlelin-1 was
specifically coupled to the absence of IP3Rs, since the myocytes
retained a normal positive inotropic response to β-adrenergic
stimulation.
4. The dilemma of cardiac IP3 receptors: lost in an ocean of
ryanodine receptors
The evidence for IP3R expression in the heart is indisputable.
Numerous laboratories using a variety of techniques have
established that cardiac myocytes possess these Ca2+ channels.
Indeed, the notion that IP3 mediates Ca
2+ release in the heart is
not new, and has been established by studies spanning the last
two decades. The very earliest studies on cardiac IP3 signaling
found evidence for functional IP3Rs capable of releasing Ca
2+
from the SR [47–51]. However, compared with Ca2+-induced
Ca2+ release through RyRs, though, the IP3-induced Ca
2+
release was slow and small. These data indicated that a major
contribution of IP3-induced Ca
2+ release to cardiac excitation–
contraction coupling was highly unlikely. As a result, IP3Rs
have been largely overlooked, and often regarded as making a
minor contribution, if any, to cardiac Ca2+ signaling.
Cardiac excitation–contraction coupling relies principally on
Ca2+-induced Ca2+ release through type 2 RyRs. Expression of
RyRs, as the major SR Ca2+ release channel in cardiac
myocytes, is large, amounting to ~500–1000 fmol/mg total
protein in ventricular myocytes from various mammalian
species [52]. This converts to ~1.5–3.5 million RyRs in a
typical ~30 pl ventricular myocyte [53]. Direct comparison of
the expression of RyRs and IP3Rs in ventricular myocytes
revealed that RyRs outnumber IP3Rs by a factor between 50:1
and 100:1 [54]. Microsomal preparations from hearts of various
species, including human, exhibit a much larger density of
RyRs than IP3Rs. For example, RyR densities amounted to
~3–4 pmol/mg protein in human ventricle [55,56] and to ~5.5–7
pmol/mg protein in dog, mouse, rabbit and rat ventricle [56].
IP3R densities, on the other hand, were ~0.09 pmol/mg protein
in bovine ventricle [16], 0.66 pmol/mg protein in canine
ventricle [32], 0.46 pmol/mg protein in ferret ventricle [57]
and 0.35 pmol/mg protein in rat ventricle [58]. Thus, on average
there appear to be ~5–80 times less IP3Rs than RyRs in
ventricular SR. These data indicate that cardiac IP3Rs face a
serious problem; they have to generate a detectable Ca2+ signal
against a large background of RyR-induced Ca2+ release. How
can so few IP3Rs have an impact on cardiac Ca
2+ signaling,
which is clearly dominated by RyRs? Or, put another way, how
can cardiac myocytes decipher and make use of a small
hormone-evoked IP3-induced Ca
2+ signal amidst the large
action potential-evoked RyR-induced Ca2+ transients?
RyRs require cytoplasmic Ca2+ increases for their activation,
and are thereby tuned to the opening of voltage-activated Ca2+channels during each action potential [59]. IP3Rs are opened by
a combination of IP3 and Ca
2+ binding [60,61]. It is generally
understood that binding of IP3 allows IP3Rs to be activated by
Ca2+ [23]. The need for synergistic binding of both IP3 and Ca
2+
explains why IP3Rs can contribute to systolic Ca
2+ transients—
they can sit with IP3 bound and wait for an activating Ca
2+
signal to arise from voltage-activated channels or neighboring
RyRs. However, IP3 binding not only allows IP3Rs to be
activated by Ca2+, it also increases their sensitivity to Ca2+. So,
with substantial increases of intracellular IP3 concentrations as
may occur following stimulation of cardiomyocytes with Gq
protein-coupled agonists, IP3Rs can become activated at normal
diastolic Ca2+ levels, or during the recovery of a stimulated
Ca2+ transient [62]. The promiscuous opening of IP3Rs during
the otherwise quiescent diastolic period under these conditions
is therefore the cause of arrhythmic Ca2+ transients and their
associated electrical activity [63,64].
5. General considerations on IP3 and intracellular Ca
2+
homeostasis
Since IP3 releases Ca
2+ from Ca2+ stores within cardiac
myocytes, it affects cellular Ca2+ homeostasis. Cellular Ca2+
homeostasis is governed by influx and efflux of Ca2+ into and
out of the cell, respectively, by intracellular Ca2+ buffering as
well as by Ca2+ storage in, distribution between and release
from intracellular compartments. The major Ca2+ store in cardiac
myocytes is the SR. Depending on species and experimental
conditions, SR Ca2+ release contributes ~50–90% of Ca2+ to the
electrically stimulated (action potential-induced) global Ca2+
transient [53]. For sustained increases of Ca2+ transients to occur,
SRCa2+ load and hence the amount of Ca2+ released from the SR
during an action potential have to increase. SR Ca2+ load is
governed by the balance between Ca2+ release or “leak” from
the SR and Ca2+ uptake into the SR. The former is mediated
mainly by SR Ca2+ release channels, i.e. RyR2 and IP3Rs, the
latter by the SR Ca2+ pump (SERCA2a), which is regulated by
phospholamban. Elegant quantitative studies have shown that it
is not sufficient to enhance SR Ca2+ release alone to arrive at a
sustained increase of the Ca2+ transient. Rather, uptake has to be
increased in parallel (as occurs, for example, during β-
adrenergic stimulation), because of SR Ca2+ autoregulation
[65,66]. For example, when RyR2 open probability is increased
selectively (through application of low concentrations of
caffeine), global Ca2+ transients are enhanced at first, but then
decline to reach steady-state amplitudes that are identical to the
pre-caffeine amplitudes [67]. This is because some of the extra
Ca2+ released from the SR is exported from the cell through
sarcolemmal mechanisms (i.e. largely NCX), which reduces SR
Ca2+ load. Reduced SR Ca2+ load, in turn, limits SR Ca2+
release because of the steep dependence of release on load [68],
which is ultimately caused by the dependence of RyR2 open
probability on SR luminal Ca2+ concentration [69]. A similar
situation might arise when IP3 concentration is elevated (e.g. by
Gq protein-coupled agonists like endothelin-1). Under these
conditions, the global Ca2+ transient is expected to increase
because of the extra Ca2+ released from the SR by activated
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2+ transients, there will be a net
loss of Ca2+ from the cell via sarcolemmal NCX. This should
reduce SR Ca2+ load and hence limit the steady-state amplitude
of the Ca2+ transient to the amplitude reached before elevation of
IP3 concentration took place. This is, however, not what is
observed experimentally. As outlined below, exposure of cardiac
myocytes to Gq protein-coupled agonists or membrane-perme-
able analogues of IP3 causes a sustained increase in global Ca
2+
transients, e.g. [63,70–72], with SR Ca2+ load staying unchanged
or even tending to decrease [72]. Thus, IP3 uniquely alters cardiac
excitation–contraction coupling in that it increases Ca2+
transients and fractional SR Ca2+ release at largely unaltered
SR Ca2+ load. This finding implies that, in addition to increasing
SR Ca2+ release during systole through activation of IP3Rs, IP3
affects cellular Ca2+ homeostasis in yet another way. In fact, Gq
protein-coupled agonists or IP3 may also increase diastolic
cytoplasmic Ca2+ concentration [17,70] and alter the kinetics of
the cytoplasmic Ca2+ transient with a prolongation of the rising
phase and an acceleration of the decay [72]. Clearly, future
studies should aim at analyzing IP3 effects on cellular Ca
2+ fluxes
in a more quantitative way, which will help gain more insight into
the actions of IP3 on cellular Ca
2+ homeostasis.
6. Elementary IP3-induced Ca
2+ release events in cardiac
myocytes
Discrete, non-propagating elementary Ca2+ release events
have been characterized in a variety of excitable and non-
excitable cell types (for reviews see [73,74]), for both RyRs
(‘Ca2+ sparks’; [75–78]) and IP3Rs [70,79,80]. Ca
2+ sparks
represent Ca2+ release from a restricted number of clustered
RyRs opening in concert [81]. It is well established that Ca2+
sparks represent the elementary Ca2+ release events that
spatially and temporally summate to produce the global Ca2+
transient during cardiac excitation–contraction coupling.
IP3R-dependent elementary Ca
2+ release events, termed
‘Ca2+ blips’ (single channel event) and ‘Ca2+ puffs’ (multi-
channel event originating from a group of IP3Rs), have been
observed in non-excitable cells such as oocytes [79], HeLa
[82] and vascular endothelial cells [80]. Ca2+ puffs differ from
RyR-mediated Ca2+ sparks in having significantly slower
kinetics. Despite the growing evidence that IP3R-evoked Ca
2+
release occurs in cardiac cells, reports of elementary Ca2+
signals arising from IP3Rs in cardiac myocytes have been
scarce. This is likely related to the significantly lower density
of IP3Rs, which practically means that Ca
2+ puffs are difficult
to discern in the 'Ca2+ noise' from RyR-dominated Ca2+
release. A recent report showed that this problem could be
circumvented experimentally by eliminating Ca2+ release via
RyRs pharmacologically [70]. This is illustrated in Fig. 1.
Permeabilized cat atrial myocytes displaying spontaneous Ca2+
release activity were treated with the RyR inhibitor tetracaine
[83], to block Ca2+ sparks. The cells were then exposed to IP3,
which resulted in the appearance of localized non-propagating
Ca2+ elevations that were completely abolished by the IP3R
blocker heparin. In comparison to typical Ca2+ sparks, the IP3-
evoked Ca2+ puffs had amplitudes which were 75–80% smallerand were about 3 times longer-lasting, and their rise time was
prolonged approximately twofold. The spatial spread of the
RyR- and IP3R-mediated elementary events did not differ
significantly (for average numbers see Fig. 1D). However, the
underlying Ca2+ release flux was clearly smaller for Ca2+ puffs
compared to Ca2+ sparks and the declining phase of [Ca2+] was
prolonged (Fig. 1C). In summary, the IP3-dependent elemen-
tary Ca2+ release events in permeabilized atrial myocytes were
distinctly different from Ca2+ sparks and were reminiscent of
Ca2+ puffs typically observed in non-excitable tissue where
IP3-dependent Ca
2+ signaling is predominant [79,80,82,84].
These data are consistent with the notion that IP3Rs provide a
significantly smaller Ca2+ release pathway compared to RyRs.
However, their relative paucity does not eliminate their
potential to affect cardiac Ca2+ signaling. It is plausible that
IP3R-dependent Ca
2+ puffs can summate with RyR-mediated
Ca2+ sparks to increase the amplitudes of electrically-evoked
Ca2+ transients. In addition, Ca2+ puffs may activate
neighboring RyRs via Ca2+-induced Ca2+ release and thereby
amplify SR Ca2+ release. Alternatively, IP3-mediated Ca
2+
signals may have distinct functions of their own due to spatial
separation from the machinery underlying excitation–contrac-
tion coupling. These possibilities are discussed further below.
7. IP3 signaling in cardiac development
The heart is one of the first organs to develop in a growing
embryo. As the heart is formed, its cells acquire the abilities to
generate pulsatile Ca2+ signals, to become electrically active and
to contract. A number of studies, using either pre-natal cardiac
cells or embryonic stem cell-derived myocytes, have indicated
that IP3Rs may play a significant role in the development of the
heart by contributing to the initiation of pacemaking activity,
and thereby promote cardiogenesis. Spontaneous Ca2+ oscilla-
tions begin as soon as the heart tube is created. These Ca2+
signals are necessary to drive contraction, as well as appropriate
gene transcription and structural arrangement of the nascent
cardiomyocytes [85]. Indeed, inhibition of the Ca2+ oscillations
or buffering the Ca2+ changes prevents development of the heart
[86].
As described above, type 2 RyRs underlie the release of Ca2+
during systole in adult and neonatal cells. Mice lacking type 2
RyRs die as embryos around E10 with major cardiac defects [87]
because the excitation–contraction coupling system cannot
mature. However, repetitive Ca2+ signals and rhythmic contrac-
tions occur in these RyR-deficient animals at E7–9.5 [87,88]. In
addition, the Ca2+ signals in young embryonic heart cells are
insensitive to experimental maneuvers that inhibit voltage-
activated Ca2+ channels or Na+/Ca2+ exchange, but are affected
by agents that deplete intracellularCa2+ stores [89] (but see [90] for
an alternative view). Taken together, these data indicate that
periodic Ca2+ release from intracellular stores occurs in young
embryonic heart cells, and that the channels involved are notRyRs.
There is accumulating evidence that IP3Rs may be respon-
sible for the early cycling of Ca2+ in developing myocytes prior
to the maturation of excitation–contraction coupling. For
example, the spontaneous Ca2+ oscillations in murine
Fig. 1. Elementary IP3-induced Ca
2+ release events in cardiac myocytes. (A) Confocal linescan image of Ca2+ sparks in a permeabilized cat atrial myocyte (control).
Tetracaine (Tetrac) abolishes Ca2+ sparks. Addition of IP3 elevates baseline Ca
2+ concentration and causes the appearance of smaller Ca2+ release events, i.e. Ca2+
puffs, which are suppressed by heparin. (B) Averaged Ca2+ spark and Ca2+ puff. (C) Normalized Ca2+ spark (black) and Ca2+ puff (red) (top) and first derivative thereof
(bottom), a measure for the underlying Ca2+ release flux. The Ca2+ puff exhibits slower kinetics and lower Ca2+ release flux than the Ca2+ spark. (D) Surface plots of
averaged linescan images of Ca2+ sparks and Ca2+ puffs. The Ca2+ puff displays lower amplitude, longer rise time and duration, and similar width as compared to the
Ca2+ spark. Modified from [70]. Copyright of the Journal of Physiology; used by kind permission.
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antagonist [42]) [89]. Furthermore, IP3Rs are expressed in the
inner mass of embryos at E5.5, and are clearly evident within the
developing heart tube at E8.5 [91]. In contrast, RyRs are not
abundant until E8.5 or later [91]. These data indicate that IP3Rs
are expressed earlier than RyRs in the developing heart, and the
timing of their expression correlates closely with the on-set of
Ca2+ oscillations.
Stem cell-derived myocytes grown in vitro can recapitulate
the development and differentiation of cardiomyocytes very
closely [92–94]. The accessibility of these cells and the relative
ease by which they can be genetically manipulated (compared to
myocytes in early embryos) has led them to be used for many
studies of cardiac development. It is established that these cells
express IP3Rs when they are in either a proliferative state or
during differentiation into cardiomyocytes [95]. Similar to their
in vivo counterparts, stem cell-derived myocytes start to show
spontaneous Ca2+ oscillations, membrane depolarizations and
contractions long before the cells have terminally differentiated.
The mechanism underlying the acquisition of spontaneousactivity in these cells is not fully clear. Likely candidates could
be the hyperpolarization-activated cyclic nucleotide-gated
cation (HCN) channels that are responsible for pacemaking
currents (If) in adult tissue [96]. However, the spontaneous Ca
2+
oscillations appear to precede the appearance of substantial
HCN-mediated currents, and the activity persists in the presence
of If inhibitors [97]. Furthermore, repetitive Ca
2+ transients
could still be observed in cells that were fully depolarized (using
K+ application), thereby precluding the involvement of
membrane potential oscillations [98]. In contrast, transfection
of early stem cell-derived myocytes with antisense cDNA to
reduce expression of type 1 IP3Rs, or application of an IP3R
antagonist, significantly reduced the spontaneous beating
[92,97]. The effect of antagonizing IP3Rs diminishes over time
[99], suggesting that IP3-driven signals progressively give way
to other mechanisms that generate Ca2+ oscillations [100]. As
expected of a pacemaking messenger, stimulating IP3 produc-
tion in stem cell-derived myocytes using hormonal agonists had
a positive chronotropic effect, which was antagonized by either
IP3R or phospholipase C inhibitors [101].
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IP3Rs in triggering the first few days of Ca
2+ cycling within the
developing heart, and consequently allowing the cardiac cells
to differentiate appropriately. After a short while, the Ca2+
cycling switches to a reliance on If, voltage-activated Ca
2+
channels and RyRs. However, IP3Rs are not entirely lost
during fetal development. Indeed, neonatal animals have a
relatively high expression of IP3Rs (compared to adult cells),
and the channels are demonstrably functional. For example,
addition of IP3 to permeabilized cells, or uncaging of photo-
releasable IP3, has directly demonstrated the presence of active
IP3Rs in situ within neonatal myocytes [102,103]. Further-
more, neonatal cardiac myocytes respond to several agonists
(e.g. endothelin-1, angiotensin II, phenylephrine, ATP, pros-
taglandins, IGF-1) with IP3 production and Ca
2+ mobilization
[102,104]. These same agonists also promote hypertrophic
growth of neonatal cardiac myocytes [104,105]. Studies using
immunostaining, Western blotting and analysis of mRNA have
suggested that IP3R types 1, 2 and 3 are expressed in neonatal
cells [102,103,106].
A consistent message from the investigations of neonatal
myocytes is that IP3 causes perinuclear Ca
2+ release. Almost all
studies that examined either the distribution of IP3Rs, or the
spatial pattern of IP3-evoked Ca
2+ signals, have reported that the
channels are largely expressed in close proximity to the nucleus
in neonatal cells [102,103,106–108]. This is unlike RyRs, which
have a more widespread expression pattern in neonatal cells
[102]. The perinuclear release of IP3-sensitive Ca
2+ stores can
impact specifically on nucleoplasmic Ca2+ levels [103] and
thereby promote hypertrophic gene transcription [109].
The overall picture that emerges from the studies of
embryonic tissues and stem cell-derived cardiomyocytes is
that IP3Rs are expressed in cardiac precursor cells, and are
relatively abundant at the very earliest stages of heart
development when they may play a critical role in develop-
ment. Their expression declines as the cells differentiate and
other Ca2+-handling systems are put into place. However,
IP3Rs are not completely lost. They are retained in the heart for
the duration of fetal development and can be readily
demonstrated in neonatal cardiac myocytes, and their expres-
sion persists into adulthood.
It should be noted that mice deficient in cardiac expression
of type 2 IP3Rs are viable and do not have any apparent cardiac
defects [17]. Furthermore, complete single deletion of type 1,
type 2 or type 3 IP3Rs in mice, or combined knockout of types
2 and 3 IP3Rs, does not prevent the murine heart (or whole
animal) from developing [110,111]. These data could indicate
that IP3Rs are not essential for cardiogenesis. However, it is
possible that there is functional redundancy between IP3R
isoforms, such that the presence of any one of the three
isoforms will do. Alternatively, another Ca2+ signaling
mechanism could compensate for the normally undertaken by
IP3Rs. Although knockout of types 2 and 3 IP3Rs appears to be
benign, mice not expressing type 1 IP3Rs mostly die in utero
[110]. It would be interesting to know if a lack of cardiac
development was partially responsible for the increased
mortality of these animals.8. IP3 signaling in atrial myocytes
There is substantial evidence for IP3-mediated Ca
2+ signal-
ing in atrial cells. The atrial myocardium expresses numerous
receptors coupling to the PIP2-PLC-IP3 cascade. Increased
phosphoinositide breakdown and inositol phosphate generation
in atrium is mediated by receptors for acetylcholine (muscari-
nic, M1 and M3), angiotensin II (AT1), endothelin (ETA),
histamine (H1), 5-hydroxytryptamine (5-HT2), norepinephrine
(α1) and vasopressin in various species including cat, chick,
guinea-pig, mouse, rat and human [10,112–125]. Furthermore,
expression of IP3Rs in atrial myocytes has been demonstrated at
mRNA and protein levels in various organisms, including
mouse, rabbit, rat and human [15,17,41,58]. Myocytes from
animal atrium are particularly rich in type 2 IP3Rs and may also
express type 3 IP3Rs [41]. Human atrial myocytes, on the other
hand, have been suggested to express predominantly type 1
IP3R [15], although this requires further clarification.
Early evidence for an involvement of IP3 in the regulation of
atrial contraction came from the observation that phosphoinosi-
tide breakdown and inositol phosphate generation were
accompanied by a positive inotropic effect [114–117,119–
121]. Direct application of IP3 to permeabilized atrial muscle
[50], photorelease of IP3 [126] and, more recently, exposure of
isolated atrial myocytes to a membrane permeable analogue of
IP3 [58,63,127,128] provided definitive proof that IP3 induces a
positive inotropic effect in atrium. Thus, an important action of
IP3 in atrium is to increase the force of contraction.
Interestingly, receptor-mediated inositol phosphate produc-
tion and expression of IP3Rs are larger in atrium than in
ventricle [10,17,41,58,113]. For example, maximal muscarinic
receptor-mediated inositol phosphate accumulation was N12-
fold in guinea-pig atrial myocytes but only 7-fold in ventricular
myocytes [10]. Similarly, in cat myocardium, muscarinic
receptor stimulation induced larger increases in phosphatidyli-
nositol breakdown in atria than in ventricles [113]. In rat and
rabbit myocytes, expression of IP3Rs is ~3.5–10 times larger in
atrial as compared to ventricular myocytes [41,58]. Microsomal
preparations from human and sheep atrium displayed RyR
densities of ~0.3–0.7 pmol/mg protein [129,130]. In contrast,
IP3R density amounted to 1.8 pmol/mg protein in rat atrium
[58]. Thus, atrial SR contains more IP3Rs, but less RyRs, than
ventricular SR, suggesting that SR Ca2+ release in atrial
myocytes is more dependent on IP3 signaling than in ventricular
myocytes. In line with this notion, direct application of IP3 to
permeabilized rat myocytes revealed a ~5 times larger global
Ca2+ increase in atrial than in ventricular myocytes [58]. Taken
together, these data might explain, at least in part, why many
transmitters and hormones coupling to the PIP2-PLC-IP3
cascade exert comparatively large positive inotropic effects in
the atrium but only small or no positive inotropic effects in the
ventricle (e.g. angiotensin II [131] or 5-hydroxytryptamine
[124]).
IP3 does not alter myofilament Ca
2+ responsiveness [48].
Rather, the positive inotropic effect of IP3 in atrial myocardium
is mediated by enhanced Ca2+ release from the SR. The extra
component of Ca2+ mobilization from IP3Rs adds to the action
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increases the Ca2+ transient underlying contraction. Potentiation
of Ca2+ transients following activation of IP3Rs has been
observed during stimulation of cat, mouse, rabbit and rat atrial
myocytes with endothelin-1 or a membrane-permeant form of
IP3 (IP3BM) [17,63,70–72,127,128]. The increase in the
electrically-stimulated Ca2+ transient occurred without altera-
tion of the Ca2+ load within the SR [72]. Thus, IP3 increased
fractional Ca2+ release from the SR (by ~13%) and did not
affect SR Ca2+ storage per se [17,72].
IP3-induced Ca
2+ release may also lead to arrhythmogenic
alterations in atrial Ca2+ signaling. In cat and rabbit atrial
myocytes, endothelin-1 induced Ca2+ alternans [70,132], which
may degenerate into arrhythmogenic Ca2+ waves [133].
Furthermore, endothelin-1 or IP3BM elicited spontaneous
Ca2+ release events during diastole in cat, mouse, rabbit and
rat atrial myocytes. These spontaneous signals ranged from
spark-like events and Ca2+ waves to extra action potential-
derived global Ca2+ transients [63,70,71,128,132]. Similarly,
in human atrial myocardium, endothelin-1 induced arrhythmic
extra contractions mediated by activation of PLC and IP3Rs
[134,135] and in isolated human atrial myocytes angiotensin
II, another agonist coupling to PLC–IP3 signaling, increased
the frequency of spontaneous Ca2+ sparks without altering SR
Ca2+ load [136].
IP3-induced arrhythmogenic Ca
2+ release likely involves the
recruitment of RyRs via Ca2+-induced Ca2+ release. In rat atrial
myocytes, some IP3Rs and RyRs are colocalized in the
subsarcolemmal area closely apposed to the sarcolemmal Na+/
Ca2+ exchanger (NCX), as illustrated in Fig. 2. The proximity of
the two types of Ca2+ channels makes it likely that activation of
IP3Rs will provoke RyR opening. The consequent Ca
2+ signal
would then activate the nearby NCX, thereby generating a
depolarizing current. Recruitment of multiple IP3R/RyR
clusters, during hormonal stimulation, can lead to sufficient
NCX activation for a full depolarization of the cell. In turn,
cellular depolarization will evoke a global diastolic Ca2+
transient. In support of this scheme, it has been demonstrated
that the spontaneous diastolic action potential-evoked Ca2+Fig. 2. Colocalization of subsarcolemmal IP3Rs and RyRs in atrial myocytes. (A) Co
(red) and RyRs (green). N denotes the nucleus. The area marked by the dashed white
occurs in some areas underneath the sarcolemma. (C) Schematic illustration of coloc
the Journal of Physiology; used by kind permission.transients observed during endothelin-1 or IP3BM application
are preceded by subsarcolemmal Ca2+ release events (probably
IP3R-activated Ca
2+ sparks; [63]). Furthermore, in human atrial
myocardium, inhibition of RyRs suppressed endothelin-1-
induced arrhythmias. These data suggest that the relatively
few IP3Rs in the atrium can cause a disproportionately large
Ca2+ release due to amplification from nearby RyRs, and thereby
induce NCX-triggered arrhythmias. Since reduction of SR Ca2+
load did not affect the arrhythmias [135] and, moreover,
endothelin-1 did not alter the SR luminal Ca2+ content
[17,72], SR Ca2+ overload can be ruled out as a causative factor
[135]. Thus, atrial arrhythmias elicited by IP3 appear to be
distinctly different from classical triggered arrhythmias as may
occur following digitalis exposure or excessive β-adrenergic
stimulation. Although both are initiated by diastolic SR Ca2+
release and subsequent activation of NCX, in the former case
Ca2+ release occurs at normal SR Ca2+ load whereas in the latter
case Ca2+ release is the result of SR Ca2+ overload.
IP3Rs are distributed not only in the subsarcolemmal/
cytoplasmic compartment of atrial cells, but also in the
perinuclear area, giving rise to the notion that they might
control nuclear Ca2+. Direct functional evidence for this has
been obtained recently in cat, rabbit and rat atrial myocytes
[71,72,137]. In permeabilized cat atrial myocytes (Fig. 3A), IP3
or adenophostin elicited increases in nuclear Ca2+ that could be
blocked by IP3R antagonists [137]. In isolated nuclei (from
whole hearts, Fig. 3B), this IP3-induced Ca
2+ release was
observed both at the outer and inner face of the nuclei
suggesting that functional IP3Rs may be expressed at the outer
and inner sides of the nuclear envelope facing the cytoplasm
and the nucleoplasm, respectively [137]. Conversely, when the
nuclear envelope was loaded with the low affinity Ca2+ dye
fluo-5N to measure nuclear envelope Ca2+ concentration
directly (Fig. 3C), IP3 reduced the Ca
2+ stored in the nuclear
envelope [137]. Consistent with these findings from permeabi-
lized myocytes and isolated nuclei, in electrically stimulated
intact atrial myocytes, endothelin-1 augmented nuclear Ca2+
transients through IP3 signaling beyond the increase seen in the
cytoplasm [71,72]. At threshold concentrations, endothelin-1nfocal image of a rat atrial myocyte immunostained for the expression of IP3Rs
rectangular is shown enlarged in (B). Colocalization of IP3Rs and RyRs (yellow)
alization of subsarcolemmal IP3Rs and RyRs. Modified from [63]. Copyright of
Fig. 3. IP3-dependent nuclear Ca
2+ signaling in cardiac myocytes. (A) Confocal
images of a permeabilized cat atrial myocyte. In the presence of 0.7 mM
tetracaine, IP3 increases nuclear Ca
2+ concentration. The IP3-induced nuclear
Ca2+ increase is partly reversed by the addition of heparin (Hep). (B) Confocal
images of an isolated rat cardiac nucleus. The nucleus and the solution
surrounding the nucleus contained fluo-4 dextran. Fluorescence changes from
the regions marked by the dashed black line (nucleus) and the area delimited by
the nuclear border and the dashed white line (‘cytoplasm’) are shown below. The
IP3-induced Ca
2+ increase is larger in the nucleus (black) than in the adjacent
cytoplasm (red). (C) Confocal images of an isolated rat cardiac nucleus. The
nuclear envelope (NE) has been loaded with the low affinity Ca2+ dye fluo-5N.
Addition of IP3 causes a reduction of Ca
2+ stored in the NE. The Ca2+ ionophore
A23187 further depletes NE Ca2+. Modified from [137]. Copyright of the
Journal of Physiology; used by kind permission.
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[72].
Collectively, these data show that in atrium IP3 may not only
increase contractility via elevated Ca2+ transients, but that it also
may induce arrhythmias and alter nuclear Ca2+ signaling to
promote remodeling and regulate excitation–transcription
coupling. Thus, it appears as if the adverse actions of atrial
IP3 signaling outweigh the beneficial effects. Clearly, furtherwork is required to define more precisely the physiological and
pathological roles of IP3 signaling in atrial myocardium.
9. IP3 signaling in ventricular myocytes
There is abundant evidence that IP3Rs are expressed in
mammalian ventricular myocytes [19,58,138]. IP3R expression
has been qualified using real-time PCR [58], Northern blotting
[19,91], Western blotting [17,41,58], immunofluorescence
[18,41,139] and IP3 binding [58,139]. A number of studies
have shown that ventricular myocyte IP3Rs are functional and
have access to replete Ca2+ stores in situ. For example, IP3 has
been shown to directly release Ca2+ from permeabilized/
fractionated ventricular cells [41,140,141]. In addition, IP3Rs
have been purified from ventricular myocytes, incorporated into
lipid membranes and shown to open after addition of IP3 [57].
Although published data have suggested that all three IP3R
isoforms are expressed in ventricular myocytes, the majority of
recent reports concur that type 2 IP3Rs constitute the
predominant channel isoform [17,18,41,58].
Despite the numerous lines of evidence for their expression
and activity, the functional roles of ventricular IP3Rs are still
unclear. Although it is apparent that IP3Rs can mobilize Ca
2+
from stores within ventricular myocytes [41,140], it is not yet
clear what and where these stores are. Furthermore, it is
striking that IP3Rs could have any significant effect on
myocyte behavior in midst of the large Ca2+ fluxes that occur
from RyRs during each heartbeat. Ventricular myocyte IP3Rs
are ~5 times less abundant than in atrial cells [17,41,58], and it
is generally estimated that IP3Rs are outnumbered by RyRs by
a ratio of ~100:1.
The most obvious function for IP3Rs would be to act as an
inotropic support for the ventricles by boosting the amplitude of
systolic Ca2+ transients, and thereby increasing contractile
force. Consistent with this notion, IP3Rs have been localized
close to the dyadic junctions where excitation–contraction
coupling is initiated [142], and direct activation of IP3Rs was
found to enhance Ca2+ spark occurrence throughout ventricular
cells [41]. Furthermore, application of hormones that activate
the production of IP3 inside ventricular myocytes, such as
endothelin-1 [11], enhances systolic Ca2+ signals in rat and
rabbit cells [41,128,143]. IP3 can therefore be considered as a
bona fide inotropic agent in some mammalian ventricular
myocytes (but perhaps not all; see [41]). However, while
positive inotropy is a beneficial effect of IP3R activation, the
situation is not that straightforward. Rather than reinforcing
their positive contribution to inotropy, the overwhelming
majority of studies that have examined the consequence of
activating IP3Rs in ventricular myocytes have concluded that
the predominant effect is to stimulate arrhythmias [62,143].
Indeed, IP3R activity has been suggested to underlie ventricular
arrhythmias resulting from hormonal stimulation [143], reper-
fusion [144,145], engagement of cytotoxic T-lymphocytes
[146] and FAS receptor activation [147]. These data suggest
that Ca2+ flux through the relatively few IP3Rs in ventricular
myocytes is perhaps more dangerous than beneficial, similar to
the situation discussed above for atrial cells.
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logical/pathological function of IP3Rs in ventricular myocytes
is their localization close to the nucleus. A substantial
proportion of IP3Rs in adult ventricular cells is expressed on
unspecified membranes close to the nucleus, or indeed on the
nuclear envelope [18,148]. Furthermore, it has been shown
that IP3 can release Ca
2+ from the ventricular myocyte nuclear
envelope (and also probably from adjacent connected
membrane compartments) [140,141]. This strategic position-
ing of a population of nucleus-associated IP3Rs potentially
allows the generation of autonomous nuclear Ca2+ signals,
which may have a significant role in regulating cardiac gene
transcription, and plausibly controlling processes such as
cardiac hypertrophy. Indeed, it has been demonstrated that the
release of perinuclear IP3-sensitive Ca
2+ stores promotes a
CaMKII-dependent phosphorylation of histone deacetylase 5
(HDAC5) thereby causing it to be exported out of the nucleus
[140]. Thus, perinuclear IP3-evoked Ca
2+ signals can de-
repress the expression of genes that underlie hypertrophic
growth, such as those under the control of MEF2c [149]. It is
well known that stimulation of myocytes with hormones that
activate IP3 production, e.g. ET-1, can promote hypertrophy
[150–154]. What is not fully understood, however, is how
such hormones can affect subtle changes in Ca2+-dependent
gene transcription inside cells that experience periodic surges
of Ca2+ during excitation–contraction coupling [155]. Peri-
nuclear IP3Rs may provide a resolution to this conundrum by
providing a source of Ca2+ signals that can be spatially and
temporally dissociated from those that regulate contraction
[156]. Consistent with this model, it has been demonstrated
that activation of IP3Rs in rat neonatal ventricular myocytes
using a membrane-permeant IP3 analogue or an α1-adrenergic
agonist causes perinuclear Ca2+ release events, and that
blocking IP3R opening decreases hypertrophic growth in
response to phenylephrine stimulation [109]. Similar findings
were made using mouse neonatal cells stimulated with ET-1
and phenylephrine; nuclear-associated IP3Rs triggered nucleo-
plasmic Ca2+ signals and hypertrophic gene transcription
[157]. Further work is required to establish whether this
scheme is relevant in vivo. However, the concept that IP3Rs
impact specifically on nuclear Ca2+ signaling is gaining
momentum. Numerous recent reports examining Ca2+ signal-
ing in neonatal [103,108,109,157], atrial [71,72,137] and
ventricular myocytes [140] have demonstrated specific effects
of IP3-generating agonists or IP3 itself on nucleoplasmic Ca
2+
signals. Coupling these data with the observations that IP3 is
necessary for some forms of hypertrophy [109,157,158] raises
the possibility that IP3Rs are key regulators of cardiac
myocyte gene transcription and fate.
10. IP3Rs in other cardiac cells
The majority of studies examining cardiac IP3R expression
and function have focused on developing embryonic/neonatal
cells, or adult atrial and ventricular myocytes. However, there
are reports suggesting that IP3Rs are also expressed in other
cardiac regions/cell types, such as papillary muscle [48,159]. Ithas also been proposed that IP3Rs are functional in nodal cells
within the developing atria. Isolation of atrial cells from E14.5
mouse embryos revealed a minor population of spontaneously
active myocytes (presumed to be pacemaking cells). Transfec-
tion of an enzyme that metabolizes IP3, and thereby prevents its
Ca2+-mobilising action, or an anti-IP3R antibody, inhibited the
spontaneous activity [97]. In the sinus node of the adult
mammalian heart, spontaneously active pacemaker cells make
use of cyclic subsarcolemmal RyR-mediated SR Ca2+ release to
activate depolarizing NCX current, which contributes to
diastolic depolarization and pacemaker activity (for review
see [160]). This ‘intracellular Ca2+ clock’ is fueled by high,
cAMP-dependent Ca2+ turnover. Increases and decreases,
respectively, in intracellular cAMP levels modulate cycle
length, i.e. heart rate, in part by alterations in PKA-dependent
phosphorylation of phospholamban (and hence SR Ca2+ load
and release). Because of this Ca2+ dependence of pacemaker
activity, it appears feasible that IP3R-mediated SR Ca
2+ release
might also modulate pacemaker activity in myocytes from adult
sinus node. Direct evidence for an involvement of IP3 signaling
in the regulation of heart rate, however, is lacking. Angiotensin
II and endothelin-1 (depending on species and experimental
conditions), which are known to increase IP3 in supra-
ventricular tissue, exert positive chronotropic effects in
mammalian heart via activation of AT1 and ETB receptors,
respectively (e.g. [161,162]). Whether PLC–IP3 signaling is
involved in the positive chronotropic effects of angiotensin II
and endothelin-1 is not known at present. Evidence from
amphibian sinus venosus, however, suggests that PLC–IP3
signaling and IP3R-mediated SR Ca
2+ release depolarize the
membrane potential of pacemaker cells thereby increasing heart
rate [163].
Purkinje cells also express IP3Rs [164], seemingly to a
greater extent than either atrial or ventricular myocytes [16].
The physiological function of IP3Rs in these cells is unclear, but
they may plausibly underlie the increased automaticity of
Purkinje fibers during adrenergic stimulation [165] or following
infarct [166]. Purkinje cells from infarcted hearts show pro-
arrhythmic propagating Ca2+ waves that are reduced in
frequency and amplitude by 2-APB. Also consistent with the
notion of IP3Rs regulating automaticity of Purkinje fibers,
reduction of IP3 production using a phospholipase C inhibitor
was demonstrated to inhibit their autonomous Ca2+ spiking
[102].
An overview on the expression of IP3R isoforms in various
regions of adult myocardium and the involvement of IP3
signaling in excitation–contraction coupling, excitation–tran-
scription coupling and arrhythmogenesis is provided in Table 1
and Fig. 4, respectively. Table 1 also lists evidence in favor of
altered IP3 expression in various cardiac diseases (for a more
detailed discussion on this issue see below). It should be noted
that, unlike RyR2, IP3Rs are also expressed to a significant
amount in non-myocytes in cardiac tissue (e.g. fibroblasts,
endothelial and smooth muscle cells). Therefore, ideally
expression of IP3Rs and alterations thereof in cardiac disease
should be confirmed in cardiac myocytes. Otherwise, the
possibility exists that the findings are obscured by IP3R
Fig. 4. Overview on IP3 signaling and its involvement in excitation–contraction coupling, excitation–transcription coupling and arrhythmias in adult cardiac myocytes.
Schematic drawing of an adult cardiac myocyte showing parts of the sarcolemma, the nucleus, the SR and the myofilaments. G protein-coupled receptors (GPCR), e.g.
for angiotensin II, endothelin-1 or phenylephrine, as well as growth factor receptors (GFR) increase cytoplasmic IP3 concentration via activation of phospholipase C
(PLC). IP3Rs are found in the SR (in atrial myocytes both in the subsarcolemmal and central SR) and in the nuclear envelope, where they face both the cytoplasm and the
nucleoplasm. By contrast, RyR2s are found predominantly in the SR. IP3 signaling is involved in excitation–contraction coupling, in excitation–transcription coupling
and in the generation of arrhythmias. Excitation–contraction coupling is mediated by Ca2+-induced Ca2+ release (CICR) from the SR through RyR2. Cytoplasmic Ca2+
binds to the myofilaments and initiates contraction. IP3-induced Ca
2+ release from the SR through IP3Rs may contribute to excitation–contraction coupling by
increasing the Ca2+ transient and thus contraction. On the other hand, IP3-induced Ca
2+ release from (subsarcolemmal) SR may trigger further Ca2+ release through
neighboring RyR2 with subsequent activation of sarcolemmal NCX. This induces arrhythmias via generation of delayed afterdepolarizations and triggered activity. IP3-
induced SR Ca2+ release also generates pro-arrhythmic Ca2+ alternans. Finally, IP3 is involved in excitation–transcription coupling via modulation of nuclear Ca
2+
concentration. Nuclear Ca2+ may be increased by IP3 in three ways: (1) IP3 may increase the cytoplasmic Ca
2+ transient. Cytoplasmic Ca2+ then diffuses through the
nuclear pores into the nucleoplasm to elicit a delayed nuclear Ca2+ transient. (2) Cytoplasmic IP3 may itself diffuse through the nuclear pores into the nucleus to activate
nuclear IP3Rs facing the nucleoplasm. Ca
2+ release from the nuclear envelope, a Ca2+ store continuous with the SR, into the nucleoplasm then increases the nuclear Ca2+
concentration directly. (3) Finally, IP3 may also activate IP3Rs on the nuclear envelope facing the cytoplasm. Ca
2+ release from the nuclear envelope into the
cytoplasm may then increase nuclear Ca2+ concentration indirectly via cytoplasmic Ca2+ diffusing into the nucleus through nuclear pores. A fourth alternative (not
shown in the cartoon) is the generation of IP3 in the nucleus via nuclear GPCR coupling to the nuclear PLC-IP3 cascade. Abbreviations: CICR, Ca
2+-induced Ca2+
release; GFR, growth factor receptor; GPCR, G protein-coupled receptor; LTCC, L-type Ca2+ channel; NPC, nuclear pore complex; NCX, Na+/Ca2+ exchanger;
PLC, phospholipase C.
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all three IP3R isoforms with the IP3R type 1 being the most
abundant isoform (more than 60% of total IP3R mRNA).
Ventricular myocytes, however, do not contain IP3R type 1 (less
than 2% of total IP3R mRNA), but rather express the type 2
(85%) and 3 (14%) IP3R [57]. Thus, we have also indicated in
Table 1 whether or not IP3R expression was confirmed in
cardiac myocytes.
11. Is nuclear Ca2+ regulated independently from
cytoplasmic Ca2+? Putative relevance of IP3-dependent
nuclear Ca2+ signaling for excitation–transcription coupling
As outlined above, there is clear evidence for regulation of
nuclear Ca2+ concentration by IP3 signaling. The question
arises, however, whether nuclear Ca2+ in beating cardiomyo-
cytes can be regulated independently from cytoplasmic Ca2+,
which undergoes large changes (from ~100 nM in diastole to
N1 μM in systole) during each heartbeat. The nuclear pores,
which traverse the nuclear envelope, represent a direct
connection between cytoplasm and nucleoplasm throughwhich Ca2+ can permeate. Consequently, increases in cyto-
plasmic Ca2+ during systole also result in increases in nuclear
Ca2+ (see pathway #1 in Fig. 4). Due to a diffusional delay, the
nuclear Ca2+ transient lags behind the cytoplasmic Ca2+
transient, as visualized by confocal Ca2+ imaging [71,72,167].
Hormone-independent increases in cytoplasmic Ca2+ transients
(elicited by elevation of extracellular Ca2+) are followed by
increases in nuclear Ca2+ transients of similar magnitude [72].
Thus, cytoplasmic Ca2+ is an important determinant of nuclear
Ca2+ arguing that nuclear Ca2+ in cardiac myocytes cannot be
regulated entirely independently from cytoplasmic Ca2+. IP3
signaling, however, is able to alter nuclear Ca2+ selectively (see
pathway #2 in Fig. 4). IP3 can release Ca
2+ from the nuclear
envelope directly into the nucleoplasm through activation of
IP3Rs located at the inner face of the nuclear envelope [137].
This IP3-induced Ca
2+ release into the nucleus may be very local
[140]. It can cause selective increases in the nuclear Ca2+
transient [72], as illustrated in Fig. 5, and activate nuclear
CaMKIIδB to promote phosphorylation of HDACs and, thereby,
transcription [140]. In this way, IP3 can regulate nuclear Ca
2+-
dependent processes like transcription independently from
Fig. 5. Endothelin-1 enhances nuclear Ca2+ transients in atrial myocytes. (A) Two-dimensional confocal images of a rabbit atrial myocyte during an electrically-
stimulated Ca2+ transient before (Control) and after the addition of 10 nM endothelin-1. The nucleus is visible as the oval area in the cell center with a delayed Ca2+
increase during the rising phase and with a delayed Ca2+ decrease during the decaying phase of the Ca2+ transient. (B) Ca2+ transients (from the cell shown in A)
obtained from the entire cytoplasm (black) and the nucleus (red). Addition of 10 nM endothelin-1 (ET-1) increases the cytoplasmic and, even more pronounced, the
nuclear Ca2+ transient. When a threshold concentration of 0.1 nM endothelin-1 is applied (right; different cell), the cytoplasmic Ca2+ transient remains unaltered,
whereas the nuclear Ca2+ transient is augmented selectively. Modified from [72]. Copyright of the Journal of Cell Science; used by kind permission.d
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nuclear Ca2+ concentration.
12. Pathological relevance of IP3 signaling
IP3-induced Ca
2+ release from the SR and the nuclear
envelope may initiate arrhythmias and alter gene expression to
induce hypertrophy and heart failure, as discussed above. In line
with this notion, many signaling systems, most notably the
sympathetic, the renin–angiotensin and the endothelin system,
are activated during cardiac diseases associated with arrhyth-
mias, hypertrophy and heart failure along with alterations in the
expression of cardiac IP3Rs. Substantive evidence suggests that
IP3 signaling may be involved in the development and/or
maintenance of atrial fibrillation, reperfusion arrhythmias,
ankyrin-B-related arrhythmias, diabetic cardiomyopathy, hyper-
trophy and heart failure.
12.1. Atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia. Its
incidence increases with age, as does the expression of the IP3R
in the heart [168]. Expression of the IP3R is augmented in a dog
model of AF and in human AF [15,169,170]. Furthermore,
cardiac tissue levels of endothelin and angiotensin II are
elevated in cardiac diseases associated with AF. Both endothelin
and angiotensin II increase IP3 generation [122,123] and elicit
arrhythmias in isolated human atrial myocardium [134,135].Thus, endothelin- and angiotensin II-induced IP3 signaling may
be involved in the initiation and progression of AF. While
endothelin receptor antagonists have not yet been tested for their
therapeutic potential against AF, several recent clinical trials
suggest that ACE inhibition and AT1 receptor blockade reduce
the incidence of AF in patients at risk of developing the
arrhythmia (reviewed in [171]). Furthermore, mutations in the
adaptor protein ankyrin-B, which is required for post-transla-
tional stability and SR targeting of IP3Rs, are associated with
AF (see below).
12.2. Reperfusion arrhythmias
Ischemia and reperfusion can cause arrhythmias and sudden
cardiac death. Upon reperfusion after an ischemic insult, there is
a surge of IP3 concentration in cardiac myocytes. The transient
increase in IP3 concentration is the result of α1-adrenergic
receptor stimulation by norepinephrine, which is released from
sympathetic nerve endings within the heart. The increase in IP3
concentration correlates with the induction of arrhythmias,
ventricular tachycardia and ventricular fibrillation [145].
Substances able to inhibit the IP3 increase prevent the
arrhythmias [145,172,173]. Inhibition of the Na+/H+ exchanger
(NHE) and NCX is also effective against the development of the
arrhythmias [174,175]. This suggests that Na+ influx through
NHE, followed by Na+ exit and Ca2+ influx through reverse
mode NCX leads to an increase in SR Ca2+ load. IP3-induced
SR Ca2+ release with subsequent activation of forward mode
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increase in IP3 concentration has been observed in atria and
ventricles from both rat and human hearts following stimulation
with either norepinephrine or thrombin (e.g. [4,173,176,177]).
12.3. Arrhythmias related to ankyrin-B mutations
Ankyrin-B is a 220 kDa adaptor protein that directly interacts
with the IP3R in cardiac myocytes. High affinity interaction
between ankyrin-B and IP3R is required for post-translational
stability and targeting of the IP3R to SR microdomains closely
opposed to neighboring T tubules [178,179]. Loss-of-function
mutations in ankyrin-B cause reduction of IP3Rs in specialized
SR–T tubule junctions (distinct from the classical dyads) in
cardiac myocytes and are associated with arrhythmias ranging
from bradycardia, sinus arrhythmia, atrial fibrillation and
catecholaminergic polymorphic ventricular tachycardia to
ventricular fibrillation both in humans and in mice heterozygous
for a null mutation in ankyrin-B (ankyrin-B+/− mice) [142,180].
In patients affected by ankyrin-B mutations, emotional or
physical stress may lead to syncopes and sudden death. The
cellular mechanisms underlying the ankyrin-B-related arrhyth-
mias may involve altered Na+ and Ca2+ homeostasis. The
macromolecular complex in the SR–T tubule junctions is
composed of ankyrin-B, IP3R and the Na
+-dependent transpor-
ters NCX and Na+/K+ pump. Loss-of-function mutations in
ankyrin-B disrupt this macromolecular complex. Cardiac
myocytes from ankyrin-B+/− mice exhibit normal resting
[Ca2+] levels and unaltered L-type Ca2+ currents but increased
Ca2+ transients and an increased propensity toward catechola-
mine-induced arrhythmogenic SR Ca2+ release [142] pointing
to SR Ca2+ overload as a causative factor. It has been suggested
that IP3Rs act as “Ca
2+ pressure valves” releasing Ca2+ from
the SR, which is subsequently eliminated by the nearby NCX
[179]. Thus, ankyrin-B-related arrhythmias represent another
example for the importance of the subcellular distribution of the
IP3R for cardiac function.
An interesting feature of the above hypothesis is that loss-of-
function of IP3Rs (or mis-targeting) appears to be responsible
for the ankyrin-B-related arrhythmias, which may ultimately be
triggered by RyR-mediated SR Ca2+ release due to SR Ca2+
overload. This is in striking contrast to the arrhythmias triggered
directly by activation of IP3Rs and IP3R-induced SR Ca
2+
release at normal SR Ca2+ load. Thus, both activation and loss-
of-function of IP3Rs may be involved in the generation of
cardiac arrhythmias.
12.4. Diabetic cardiomyopathy
Diabetic cardiomyopathy is now recognized as a distinct
clinical entity with characteristic structural and functional
changes of the heart. Ca2+ homeostasis is altered in myocytes
from diabetic hearts such that electrically stimulated Ca2+
transients are reduced and prolonged. These alterations are the
result of changes in the expression and function of SR Ca2+
handling proteins; SERCA2a, NCX and RyR expressions are
reduced, whereas phospholamban expression is increased andits phosphorylation decreased. As a consequence, SR Ca2+ load
is reduced, and SR Ca2+ release and re-uptake are impaired
[181,182]. Interestingly, an increased propensity toward
arrhythmogenic afterdepolarizations has been observed in
diabetic cardiomyocytes [182]. Insulin increases IP3 concentra-
tion and triggers arrhythmic Ca2+ release events in myocytes
from diabetic ob/ob mice – but not from wild-type mice – and
this effect is mediated via IP3 signaling [183]. IP3R expression
(type 1 and type 2 IP3Rs) is unaltered in ventricles from ob/ob
mice [183], but decreased in a diabetes model in the rat and in
atrium from diabetic patients [184,185]. Both increased and
decreased IP3 production in response to α-adrenergic stimula-
tion has been reported in diabetes [186,187]. PIP2 levels and the
expression and activities of PLC isoenzymes are reduced [188].
Taken together, these data indicate that altered receptor-PLC
coupling, IP3 generation and IP3-induced SR Ca
2+ release may
contribute to impaired Ca2+ handling and arrhythmogenesis in
diabetic cardiomyopathy.
12.5. Hypertrophy and heart failure
Many agonists of Gq protein-coupled receptors induce cardiac
hypertrophy that eventuallymay deteriorate into heart failure. The
best studied and, possibly, clinically most relevant examples
include angiotensin II, endothelin-1 and norepinephrine acting
predominantly via AT1, ETA and α1-adrenergic receptors,
respectively. Plasma and tissue levels of angiotensin II,
endothelin-1 and norepinephrine and receptor densities are often
increased in hypertrophy. However, a direct role for IP3 signaling
in cardiac hypertrophy has remained elusive until most recently,
since the respective receptors couple to various signaling
pathways each of which may culminate into hypertrophy.
Early evidence suggested that IP3 signaling in hypertrophy
may be unaltered or even impaired [189,190]. More recent
studies, however, collectively point toward an important role of
PLC-IP3 signaling in the development and progression of
hypertrophy. For example, in pressure overload-induced
hypertrophy, PLC activity was elevated and norepinephrine-
induced generation of IP3 was increased [191]. Moreover, IP3-
induced Ca2+ release from the SR was larger in myocytes from
hypertensive rats than from control rats [192]. In volume
overload-induced hypertrophy, sarcolemmal PIP2 levels were
decreased, whereas PLCβ1 and PLCγ1 expression and
activities and IP3 levels were increased [193]. Furthermore, in
hypertrophy induced by transient overexpression of a constitu-
tively active Gqα, PLCβ1 and PLCβ3 expressions were
elevated [194]. Thus, PLC–IP3 signaling and IP3-induced
Ca2+ release are enhanced in cardiac hypertrophy. These
findings also provide an explanation for the progressive nature
of cardiac hypertrophy: initiation of increased gene expression
through nuclear IP3-induced Ca
2+ release appears to contribute
to increased expression of the very machinery responsible for
the generation of IP3, thereby creating a positive feedback loop
[195].
Heart failure is accompanied by neurohormonal activation,
including the sympathetic nervous system, the renin–angioten-
sin system and the endothelin system. Cardiac tissue levels of
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Expression of the respective receptors (which couple to IP3
formation) is altered. In human heart failure, expression of α1-
adrenergic receptors is unchanged (but their relative expression
is increased due to a large downregulation of the predominating
β1-adrenergic receptors) [196], AT1 receptors are down-
regulated (presumably due to increased angiotensin II levels
[197]) and ETA receptors are upregulated [198,199]. In animal
models of heart failure, changes in phosphoinositide metabo-
lism occur, including alterations in the abundance, expression
and/or activity of PIP2, PI-4 kinase, PIP-5 kinase, PLC
isoforms and inositol phosphates [200,201]. Expression of
IP3Rs is increased in both human and animal heart failure,
whereas RyR levels are reduced, indicating a shift toward
more IP3R-mediated Ca
2+ release in the failing heart [19,202].
These data indicate that, in heart failure, there are complex
changes in the transmitter and receptor systems coupling to
IP3 formation as well as in the regulation of IP3Rs suggesting
that IP3-induced Ca
2+ release is involved in the development
and/or progression of the disease.
13. Unresolved questions and future perspectives
Recent years have seen tremendous advances in our
understanding of IP3 signaling in cardiac myocytes. There is
no longer any doubt that IP3 plays important physiological and
pathological roles in the heart. These roles, however, are
incompletely understood and remain to be defined more
precisely. A puzzling aspect of IP3 signaling in adult cardiac
myocytes is that apparently it exerts more adverse than
beneficial effects. Is IP3 signaling in adult myocardium a
mere remnant of the developing heart or does it serve unique
functions beyond arrhythmogenesis and induction of (mala-
daptive) remodeling? Further important but still largely
unresolved questions are: Why do cardiac myocytes express
different IP3R isoforms? How is expression of IP3Rs regulated?
What is the composition, subcellular distribution and functional
role of IP3R macromolecular complexes in cardiac myocytes?
Which kinases and phosphatases regulate cardiac IP3R
phosphorylation and what is the functional impact of this
regulation? By what other means is IP3R function regulated?
How exactly is IP3 signaling involved in the development and
progression of cardiac diseases? Future studies should aim at
answering these questions. Clearly, IP3 signaling in cardiac
myocytes will continue being an important topic in cardiac
physiology as well as cardiology. It certainly holds the promise
for further surprises and excitement.
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